Physician profile
Syed Hashmi
NPI 1164787792
$3,492.95
in general payments reported to CMS, 2019-2025
28 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $142 · 2021: $471 · 2022: $733 · 2023: $1,187 · 2024: $378 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Education: $41.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.49 |
| Education | $41.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $438.00 | 2020-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $397.94 | 2022-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $363.48 | 2019-2025 | Rayaldee |
| Amgen INC. | $313.41 | 2021-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals Lp | $265.00 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $228.07 | 2021-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $225.60 | 2022-2025 | |
| Akebia Therapeutics INC | $170.26 | 2020-2024 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $128.27 | 2020-2024 | Jynarque |
| Baxter Healthcare | $117.91 | 2019-2023 | Renal - Pd |
| Ani Pharmaceuticals, INC. | $109.03 | 2023 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $103.67 | 2023 | Xerava |
| Vifor Pharma, INC. | $73.93 | 2021-2023 | Veltassa |
| Calliditas Therapeutics US INC. | $72.11 | 2023-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $67.37 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $57.05 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $47.65 | 2022-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $46.27 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $41.05 | 2021-2024 | Crysvita |
| Travere Therapeutics, INC. | $37.70 | 2023-2025 | |
| Siemens Medical Solutions USA, INC. | $33.89 | 2021 | |
| Alnylam Pharmaceuticals INC. | $30.89 | 2021 | |
| Ardelyx, INC. | $25.95 | 2025 | Ibsrela |
| Scpharmaceuticals INC. | $23.57 | 2024 | |
| Renalytix Ai, INC. | $22.51 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Genzyme Corporation | $20.45 | 2019 | |
| Lilly USA, LLC | $16.04 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $15.88 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.